7,17-diHDPAn-3 enhances erythropoiesis without affecting thrombocyte formation. (A) Fluorescent imaging of Tg(CD41:GFP) embryos treated with 7,17-diHDPAn-3 from 48 to 72 hpf showed no significant difference in the number of GFP-positive thrombocytes compared to controls (n = 7 embryos per group). Images were taken at 10× magnification. (B) Manual counting of CD41⁺ cells in treated vs control embryos confirmed no significant difference between the groups (n = 7 embryos per group; unpaired Student t test). (C) RT-qPCR analysis of cd41 expression after treatment from 48 to 72 hpf revealed no significant difference between treated and control groups (n = 3 biological replicates per group; technical triplicates; 30 embryos per sample). (D) FACS analysis of CD41⁺ cells (marking the thrombocytes) in embryos exposed to 7,17-diHDPAn-3 from 48 to 72 hpf showed no significant change in thrombocyte cell number (n = 3 biological replicates per group; 40 embryos per sample). (E) Quantification of high GFP-positive cells as a percentage of total live single cells confirmed no significant difference between the groups (n = 3 biological replicates per group; unpaired Student t test). Bar plots represent mean ± SD. Statistical comparisons were performed using unpaired Student t tests. ctrl, control; FSC-A, forward scatter A; ns, no significant difference.